206 related articles for article (PubMed ID: 35816067)
1. Update: Mechanisms of Topical Retinoids in Acne.
Dreno B; Kang S; Leyden J; York J
J Drugs Dermatol; 2022 Jul; 21(7):734-740. PubMed ID: 35816067
[TBL] [Abstract][Full Text] [Related]
2. Management of Acne Vulgaris With Trifarotene.
Tan J; Chavda R; Baldwin H; Dreno B
J Cutan Med Surg; 2023; 27(4):368-374. PubMed ID: 36927117
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene.
Aubert J; Piwnica D; Bertino B; Blanchet-Réthoré S; Carlavan I; Déret S; Dreno B; Gamboa B; Jomard A; Luzy AP; Mauvais P; Mounier C; Pascau J; Pelisson I; Portal T; Rivier M; Rossio P; Thoreau E; Vial E; Voegel JJ
Br J Dermatol; 2018 Aug; 179(2):442-456. PubMed ID: 29974453
[TBL] [Abstract][Full Text] [Related]
4. Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments.
Chien A
J Drugs Dermatol; 2018 Dec; 17(12):s51-55. PubMed ID: 30586482
[TBL] [Abstract][Full Text] [Related]
5. An Overview on the Management of Atrophic Acne Scars: The Role of Trifarotene as an Adjunct.
Conte S; Li MK
Skin Therapy Lett; 2024 Jul; 29(4):1-4. PubMed ID: 38963911
[TBL] [Abstract][Full Text] [Related]
6. Selective RAR agonists for acne vulgaris: A narrative review.
Kassir M; Karagaiah P; Sonthalia S; Katsambas A; Galadari H; Gupta M; Lotti T; Wollina U; Abdelmaksoud A; Grabbe S; Goldust M
J Cosmet Dermatol; 2020 Jun; 19(6):1278-1283. PubMed ID: 32100454
[TBL] [Abstract][Full Text] [Related]
7. A Novel Topical Retinoid for Acne: Trifarotene 50 μg/g Cream.
Tan J; Miklas M
Skin Therapy Lett; 2020 Mar; 25(2):1-2. PubMed ID: 32196146
[TBL] [Abstract][Full Text] [Related]
8. Transcriptomics Analysis Indicates Trifarotene Reverses Acne-Related Gene Expression Changes.
Dreno B; Chavda R; Julia V; Khammari A; Blanchet-Réthoré S; Krishnaswamy JK
Front Med (Lausanne); 2021; 8():745822. PubMed ID: 34746181
[No Abstract] [Full Text] [Related]
9. Sequential Treatment With Topical Trifarotene and Injectable NASHA Gel in Acne Scars: A Case Series.
Belmontesi M
J Drugs Dermatol; 2023 May; 22(5):502-506. PubMed ID: 37133474
[TBL] [Abstract][Full Text] [Related]
10. Trifarotene: First Approval.
Scott LJ
Drugs; 2019 Nov; 79(17):1905-1909. PubMed ID: 31713811
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris.
Brumfiel CM; Patel MH; Bell KA; Cardis MA
Ther Clin Risk Manag; 2021; 17():755-763. PubMed ID: 34345173
[TBL] [Abstract][Full Text] [Related]
12. Trifarotene for the Treatment of Facial and Truncal Acne.
Bell KA; Brumfiel CM; Haidari W; Boger L
Ann Pharmacother; 2021 Jan; 55(1):111-116. PubMed ID: 32567361
[TBL] [Abstract][Full Text] [Related]
13. Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments.
Chien A
J Drugs Dermatol; 2018 Dec; 17(12):s51-55. PubMed ID: 30586483
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.
Tan J; Thiboutot D; Popp G; Gooderham M; Lynde C; Del Rosso J; Weiss J; Blume-Peytavi U; Weglovska J; Johnson S; Parish L; Witkowska D; Sanchez Colon N; Alió Saenz A; Ahmad F; Graeber M; Stein Gold L
J Am Acad Dermatol; 2019 Jun; 80(6):1691-1699. PubMed ID: 30802558
[TBL] [Abstract][Full Text] [Related]
15. Trifarotene (Aklief) - a new topical retinoid for acne.
Med Lett Drugs Ther; 2019 Dec; 61(1587):195-197. PubMed ID: 31999666
[No Abstract] [Full Text] [Related]
16. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
Thoreau E; Arlabosse JM; Bouix-Peter C; Chambon S; Chantalat L; Daver S; Dumais L; Duvert G; Feret A; Ouvry G; Pascau J; Raffin C; Rodeville N; Soulet C; Tabet S; Talano S; Portal T
Bioorg Med Chem Lett; 2018 Jun; 28(10):1736-1741. PubMed ID: 29706423
[TBL] [Abstract][Full Text] [Related]
17. Exploring the role of trifarotene against RAR-α: an investigation of expression pattern and clinicopathological significance of RAR-α in breast cancer.
Jan N; Sofi S; Abo Mansoor A; Abdelrahim A; Ahmad I; Almilabairy A; Ahmad F; Mir MA
Front Pharmacol; 2024; 15():1361679. PubMed ID: 38910889
[TBL] [Abstract][Full Text] [Related]
18. Advances in Topical Management of Adolescent Facial and Truncal Acne: A Phase 3 Pooled Analysis of Safety and Efficacy of Trifarotene 0.005% Cream.
Eichenfield L; Kwong P; Lee S; Krowchuk D; Arekapudi K; Hebert A
J Drugs Dermatol; 2022 Jun; 21(6):582-586. PubMed ID: 35674762
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.
Blume-Peytavi U; Fowler J; Kemény L; Draelos Z; Cook-Bolden F; Dirschka T; Eichenfield L; Graeber M; Ahmad F; Alió Saenz A; Rich P; Tanghetti E
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):166-173. PubMed ID: 31306527
[TBL] [Abstract][Full Text] [Related]
20. New Developments in Topical Acne Therapy.
Drake L; Reyes-Hadsall S; Barbieri JS; Mostaghimi A
Am J Clin Dermatol; 2022 Mar; 23(2):125-136. PubMed ID: 35041198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
